Concepts (224)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Erythrocyte Transfusion | 19 | 2024 | 74 | 3.250 |
Why?
|
| Anemia | 15 | 2022 | 127 | 2.180 |
Why?
|
| Critical Illness | 19 | 2022 | 321 | 2.140 |
Why?
|
| Intensive Care Units, Pediatric | 15 | 2020 | 73 | 1.510 |
Why?
|
| Fluid Therapy | 4 | 2018 | 49 | 1.480 |
Why?
|
| Water-Electrolyte Imbalance | 2 | 2020 | 10 | 1.260 |
Why?
|
| Child | 32 | 2023 | 4501 | 1.170 |
Why?
|
| Respiration, Artificial | 8 | 2023 | 297 | 1.010 |
Why?
|
| Acute Lung Injury | 2 | 2023 | 45 | 0.990 |
Why?
|
| Neuromuscular Blockade | 2 | 2023 | 8 | 0.940 |
Why?
|
| Water-Electrolyte Balance | 3 | 2020 | 17 | 0.860 |
Why?
|
| Critical Care | 17 | 2022 | 394 | 0.850 |
Why?
|
| Extracorporeal Membrane Oxygenation | 2 | 2021 | 62 | 0.810 |
Why?
|
| Ventilator-Induced Lung Injury | 2 | 2013 | 10 | 0.810 |
Why?
|
| Hemoglobins | 4 | 2023 | 135 | 0.770 |
Why?
|
| Hemostatics | 1 | 2022 | 26 | 0.770 |
Why?
|
| Delirium | 1 | 2023 | 53 | 0.770 |
Why?
|
| Respiratory Insufficiency | 3 | 2019 | 156 | 0.760 |
Why?
|
| Brain Injuries, Traumatic | 1 | 2020 | 97 | 0.570 |
Why?
|
| Infant | 12 | 2022 | 1640 | 0.520 |
Why?
|
| Phlebotomy | 2 | 2017 | 7 | 0.520 |
Why?
|
| Child, Preschool | 13 | 2020 | 1979 | 0.500 |
Why?
|
| Respiratory Distress Syndrome, Newborn | 1 | 2015 | 12 | 0.480 |
Why?
|
| Evidence-Based Medicine | 13 | 2022 | 459 | 0.430 |
Why?
|
| Hemorrhage | 3 | 2022 | 267 | 0.410 |
Why?
|
| Humans | 40 | 2024 | 63030 | 0.410 |
Why?
|
| Platelet Transfusion | 4 | 2022 | 11 | 0.340 |
Why?
|
| Infant, Newborn | 7 | 2022 | 1353 | 0.320 |
Why?
|
| Consensus Development Conferences as Topic | 2 | 2018 | 16 | 0.300 |
Why?
|
| Pediatrics | 2 | 2020 | 252 | 0.260 |
Why?
|
| Sepsis | 2 | 2022 | 286 | 0.250 |
Why?
|
| Self Report | 2 | 2019 | 374 | 0.250 |
Why?
|
| Practice Guidelines as Topic | 3 | 2018 | 729 | 0.240 |
Why?
|
| Adolescent | 8 | 2020 | 6210 | 0.230 |
Why?
|
| Blood Banks | 1 | 2024 | 9 | 0.220 |
Why?
|
| Randomized Controlled Trials as Topic | 3 | 2023 | 732 | 0.220 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2022 | 6 | 0.190 |
Why?
|
| Liver Failure, Acute | 1 | 2022 | 24 | 0.190 |
Why?
|
| Heart Defects, Congenital | 2 | 2023 | 102 | 0.190 |
Why?
|
| Transfusion Reaction | 2 | 2018 | 46 | 0.180 |
Why?
|
| Consensus | 2 | 2023 | 230 | 0.180 |
Why?
|
| Wounds, Penetrating | 2 | 1998 | 26 | 0.170 |
Why?
|
| Neoplasms | 2 | 2022 | 1353 | 0.160 |
Why?
|
| Education, Distance | 1 | 2020 | 33 | 0.160 |
Why?
|
| Liver Transplantation | 1 | 2022 | 215 | 0.160 |
Why?
|
| Thalassemia | 1 | 2018 | 4 | 0.150 |
Why?
|
| Anemia, Hemolytic | 1 | 2018 | 12 | 0.150 |
Why?
|
| Shock, Hemorrhagic | 1 | 2018 | 20 | 0.150 |
Why?
|
| Shock | 1 | 2018 | 33 | 0.150 |
Why?
|
| Renal Replacement Therapy | 1 | 2018 | 24 | 0.150 |
Why?
|
| Male | 12 | 2020 | 29655 | 0.150 |
Why?
|
| Anemia, Sickle Cell | 1 | 2018 | 63 | 0.140 |
Why?
|
| Health Personnel | 1 | 2021 | 367 | 0.140 |
Why?
|
| Graft vs Host Disease | 1 | 2018 | 111 | 0.140 |
Why?
|
| Blood Transfusion | 1 | 2018 | 161 | 0.140 |
Why?
|
| Female | 12 | 2020 | 32653 | 0.140 |
Why?
|
| Unnecessary Procedures | 1 | 2017 | 44 | 0.140 |
Why?
|
| Eligibility Determination | 1 | 2017 | 36 | 0.130 |
Why?
|
| Cross-Sectional Studies | 3 | 2018 | 2566 | 0.130 |
Why?
|
| Cohort Studies | 2 | 2014 | 2552 | 0.130 |
Why?
|
| Research Personnel | 1 | 2017 | 94 | 0.130 |
Why?
|
| Heart-Assist Devices | 1 | 2018 | 144 | 0.130 |
Why?
|
| Diet Therapy | 1 | 2015 | 15 | 0.120 |
Why?
|
| Emergency Medicine | 1 | 1998 | 188 | 0.120 |
Why?
|
| Enteral Nutrition | 1 | 2015 | 54 | 0.120 |
Why?
|
| Conscious Sedation | 1 | 2015 | 39 | 0.120 |
Why?
|
| Patient Care Planning | 1 | 2015 | 84 | 0.110 |
Why?
|
| Clinical Competence | 1 | 2020 | 722 | 0.110 |
Why?
|
| Erythrocyte Count | 3 | 2018 | 15 | 0.110 |
Why?
|
| Patient Selection | 1 | 2017 | 485 | 0.110 |
Why?
|
| Guideline Adherence | 1 | 2016 | 306 | 0.110 |
Why?
|
| Acute Disease | 1 | 2015 | 671 | 0.100 |
Why?
|
| Boston | 1 | 2014 | 251 | 0.100 |
Why?
|
| Pain Management | 1 | 2015 | 159 | 0.100 |
Why?
|
| Incidence | 2 | 2020 | 1373 | 0.100 |
Why?
|
| Retrospective Studies | 3 | 2015 | 6577 | 0.100 |
Why?
|
| Length of Stay | 1 | 2016 | 807 | 0.100 |
Why?
|
| Body Mass Index | 1 | 2016 | 863 | 0.100 |
Why?
|
| Bayes Theorem | 1 | 2012 | 122 | 0.100 |
Why?
|
| Kainic Acid | 3 | 2002 | 8 | 0.100 |
Why?
|
| Blood Specimen Collection | 1 | 2012 | 20 | 0.100 |
Why?
|
| Blood Component Transfusion | 2 | 2022 | 11 | 0.090 |
Why?
|
| Internship and Residency | 1 | 2020 | 794 | 0.090 |
Why?
|
| Plasma | 2 | 2022 | 37 | 0.090 |
Why?
|
| Hospitals, Pediatric | 1 | 2012 | 52 | 0.090 |
Why?
|
| Sex Distribution | 1 | 2012 | 253 | 0.090 |
Why?
|
| Age Distribution | 1 | 2012 | 259 | 0.090 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2016 | 712 | 0.090 |
Why?
|
| Patient Safety | 1 | 2012 | 243 | 0.080 |
Why?
|
| Severity of Illness Index | 3 | 2020 | 1543 | 0.080 |
Why?
|
| Prospective Studies | 5 | 2020 | 3264 | 0.070 |
Why?
|
| Data Interpretation, Statistical | 1 | 2008 | 194 | 0.070 |
Why?
|
| Clinical Decision-Making | 2 | 2018 | 162 | 0.070 |
Why?
|
| Cerebellum | 3 | 2002 | 93 | 0.060 |
Why?
|
| Risk Factors | 2 | 2015 | 5319 | 0.060 |
Why?
|
| Clinical Trials as Topic | 1 | 2008 | 452 | 0.060 |
Why?
|
| Neurotoxins | 2 | 2002 | 21 | 0.060 |
Why?
|
| Risk Assessment | 1 | 2012 | 2055 | 0.060 |
Why?
|
| Calcium Channels, L-Type | 2 | 2002 | 26 | 0.060 |
Why?
|
| Neurons | 2 | 2002 | 922 | 0.060 |
Why?
|
| Receptors, Glutamate | 1 | 2002 | 18 | 0.050 |
Why?
|
| Central Nervous System Diseases | 1 | 2002 | 57 | 0.050 |
Why?
|
| Adult | 5 | 2023 | 16691 | 0.040 |
Why?
|
| Reactive Oxygen Species | 1 | 2002 | 224 | 0.040 |
Why?
|
| Wound Infection | 2 | 1998 | 28 | 0.040 |
Why?
|
| New York | 2 | 1998 | 143 | 0.040 |
Why?
|
| Research | 1 | 2022 | 193 | 0.040 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2000 | 85 | 0.040 |
Why?
|
| Decision Making | 1 | 2023 | 405 | 0.040 |
Why?
|
| Suture Techniques | 2 | 1998 | 99 | 0.040 |
Why?
|
| Central Nervous System | 1 | 2002 | 197 | 0.040 |
Why?
|
| ROC Curve | 1 | 2020 | 280 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 2020 | 160 | 0.040 |
Why?
|
| Excitatory Amino Acid Agonists | 1 | 1999 | 19 | 0.040 |
Why?
|
| Wound Healing | 2 | 1998 | 189 | 0.040 |
Why?
|
| Immunocompromised Host | 1 | 2020 | 107 | 0.040 |
Why?
|
| Ion Channel Gating | 1 | 1999 | 45 | 0.040 |
Why?
|
| Carboxypeptidases | 1 | 1999 | 8 | 0.040 |
Why?
|
| Simulation Training | 1 | 2020 | 65 | 0.040 |
Why?
|
| IgA Deficiency | 1 | 2018 | 3 | 0.040 |
Why?
|
| Cardiovascular Surgical Procedures | 1 | 2018 | 8 | 0.040 |
Why?
|
| Calcium Channels | 1 | 1999 | 103 | 0.040 |
Why?
|
| Vital Signs | 1 | 2018 | 12 | 0.040 |
Why?
|
| Blood Gas Analysis | 1 | 2018 | 34 | 0.040 |
Why?
|
| Decision Trees | 1 | 2018 | 51 | 0.040 |
Why?
|
| Emergency Service, Hospital | 2 | 1998 | 1091 | 0.040 |
Why?
|
| Intubation, Intratracheal | 1 | 2020 | 204 | 0.040 |
Why?
|
| Stem Cell Transplantation | 1 | 2018 | 79 | 0.040 |
Why?
|
| Therapeutic Irrigation | 1 | 1998 | 18 | 0.040 |
Why?
|
| Antigens, Surface | 1 | 1999 | 196 | 0.040 |
Why?
|
| Hemoglobinometry | 1 | 2017 | 2 | 0.040 |
Why?
|
| Missouri | 1 | 2017 | 10 | 0.030 |
Why?
|
| Pediatric Nursing | 1 | 2017 | 12 | 0.030 |
Why?
|
| Young Adult | 2 | 2020 | 4655 | 0.030 |
Why?
|
| Utilization Review | 1 | 2017 | 32 | 0.030 |
Why?
|
| Hematocrit | 1 | 2017 | 33 | 0.030 |
Why?
|
| Blood Volume | 1 | 2017 | 42 | 0.030 |
Why?
|
| Health Plan Implementation | 1 | 2017 | 40 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 1142 | 0.030 |
Why?
|
| United Kingdom | 1 | 2017 | 80 | 0.030 |
Why?
|
| Sample Size | 1 | 2017 | 65 | 0.030 |
Why?
|
| Inservice Training | 1 | 2017 | 86 | 0.030 |
Why?
|
| Nifedipine | 3 | 2002 | 19 | 0.030 |
Why?
|
| Cerebral Hemorrhage | 1 | 2017 | 93 | 0.030 |
Why?
|
| Calcium Channel Blockers | 3 | 2002 | 59 | 0.030 |
Why?
|
| Secondary Prevention | 1 | 2017 | 163 | 0.030 |
Why?
|
| Cardiovascular Diseases | 1 | 2023 | 834 | 0.030 |
Why?
|
| Esthetics | 1 | 1995 | 19 | 0.030 |
Why?
|
| Physician's Role | 1 | 2017 | 124 | 0.030 |
Why?
|
| Fibrinolytic Agents | 1 | 2017 | 169 | 0.030 |
Why?
|
| Prognosis | 1 | 2020 | 1737 | 0.030 |
Why?
|
| Survivors | 1 | 2016 | 170 | 0.030 |
Why?
|
| Positive-Pressure Respiration | 1 | 2015 | 51 | 0.030 |
Why?
|
| Cicatrix | 1 | 1995 | 61 | 0.030 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2017 | 225 | 0.030 |
Why?
|
| Nutritional Status | 1 | 2015 | 97 | 0.030 |
Why?
|
| New England | 1 | 2015 | 273 | 0.030 |
Why?
|
| Pediatric Obesity | 1 | 2016 | 108 | 0.030 |
Why?
|
| Cell Survival | 3 | 2002 | 573 | 0.030 |
Why?
|
| Overweight | 1 | 2016 | 250 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 934 | 0.030 |
Why?
|
| Age Factors | 1 | 1998 | 1559 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2015 | 768 | 0.030 |
Why?
|
| Rats | 3 | 2002 | 1980 | 0.020 |
Why?
|
| Attitude of Health Personnel | 1 | 2017 | 588 | 0.020 |
Why?
|
| Wounds and Injuries | 1 | 1995 | 251 | 0.020 |
Why?
|
| Cells, Cultured | 3 | 2002 | 2156 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2017 | 755 | 0.020 |
Why?
|
| Registries | 1 | 1995 | 882 | 0.020 |
Why?
|
| Time Factors | 2 | 2015 | 3751 | 0.020 |
Why?
|
| Excitatory Amino Acid Antagonists | 2 | 2002 | 37 | 0.020 |
Why?
|
| Biometry | 1 | 2008 | 12 | 0.020 |
Why?
|
| Bias | 1 | 2008 | 112 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2008 | 261 | 0.020 |
Why?
|
| Patients | 1 | 2008 | 112 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 1998 | 5613 | 0.020 |
Why?
|
| Calcium | 2 | 2000 | 573 | 0.020 |
Why?
|
| Research Design | 1 | 2008 | 573 | 0.010 |
Why?
|
| Chelating Agents | 1 | 2002 | 50 | 0.010 |
Why?
|
| Electron Transport | 1 | 2002 | 36 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 2002 | 250 | 0.010 |
Why?
|
| Animals, Newborn | 1 | 2002 | 237 | 0.010 |
Why?
|
| Iron | 1 | 2002 | 146 | 0.010 |
Why?
|
| Spider Venoms | 1 | 2000 | 3 | 0.010 |
Why?
|
| Culture Media, Serum-Free | 1 | 2000 | 10 | 0.010 |
Why?
|
| Ribosomal Protein S6 Kinases | 1 | 2000 | 10 | 0.010 |
Why?
|
| Cell Membrane Permeability | 1 | 2000 | 39 | 0.010 |
Why?
|
| Middle Aged | 1 | 1998 | 17439 | 0.010 |
Why?
|
| Receptors, AMPA | 1 | 2000 | 42 | 0.010 |
Why?
|
| Cell Death | 1 | 2002 | 284 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 2002 | 198 | 0.010 |
Why?
|
| Neuroprotective Agents | 1 | 2000 | 75 | 0.010 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2000 | 171 | 0.010 |
Why?
|
| Thapsigargin | 1 | 1999 | 17 | 0.010 |
Why?
|
| 1-Methyl-3-isobutylxanthine | 1 | 1999 | 12 | 0.010 |
Why?
|
| Dizocilpine Maleate | 1 | 1999 | 10 | 0.010 |
Why?
|
| Ryanodine | 1 | 1999 | 10 | 0.010 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 1999 | 27 | 0.010 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 1999 | 21 | 0.010 |
Why?
|
| Electric Conductivity | 1 | 1999 | 52 | 0.010 |
Why?
|
| Sucrose | 1 | 1999 | 28 | 0.010 |
Why?
|
| Sodium | 1 | 1999 | 62 | 0.010 |
Why?
|
| Glutamate Carboxypeptidase II | 1 | 1999 | 7 | 0.010 |
Why?
|
| Oligopeptides | 1 | 1999 | 133 | 0.010 |
Why?
|
| Benzodiazepines | 1 | 1999 | 100 | 0.010 |
Why?
|
| Necrosis | 1 | 1999 | 144 | 0.010 |
Why?
|
| Immunoblotting | 1 | 1999 | 204 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2000 | 863 | 0.010 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 1999 | 247 | 0.010 |
Why?
|
| Mitochondria | 1 | 2002 | 370 | 0.010 |
Why?
|
| Zinc | 1 | 1999 | 92 | 0.010 |
Why?
|
| Animals | 3 | 2002 | 20656 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 1999 | 371 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 1999 | 373 | 0.010 |
Why?
|
| Insulin | 1 | 2000 | 687 | 0.010 |
Why?
|
| Binding Sites | 1 | 1999 | 903 | 0.010 |
Why?
|
| Sampling Studies | 1 | 1995 | 68 | 0.010 |
Why?
|
| Sutures | 1 | 1995 | 41 | 0.010 |
Why?
|
| Evaluation Studies as Topic | 1 | 1995 | 104 | 0.010 |
Why?
|
| Observer Variation | 1 | 1995 | 213 | 0.010 |
Why?
|
| Apoptosis | 1 | 1999 | 1073 | 0.010 |
Why?
|
| Data Collection | 1 | 1995 | 384 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 1995 | 1641 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2000 | 3033 | 0.010 |
Why?
|